Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2023 | $35.00 | Neutral | UBS |
| 12/8/2022 | $65.00 → $40.00 | Overweight → Neutral | Piper Sandler |
| 11/18/2022 | $45.00 | Outperform | Raymond James |
| 8/25/2022 | $65.00 | Outperform | Credit Suisse |
| 2/4/2022 | $80.00 | Overweight | Piper Sandler |
| 1/25/2022 | $141.00 → $125.00 | Outperform | Oppenheimer |
| 8/10/2021 | $55.00 → $65.00 | Underperform | Credit Suisse |
| 8/5/2021 | $55.00 | Underperform | Credit Suisse |
UBS initiated coverage of Fulgent Genetics with a rating of Neutral and set a new price target of $35.00
Piper Sandler downgraded Fulgent Genetics from Overweight to Neutral and set a new price target of $40.00 from $65.00 previously
Raymond James initiated coverage of Fulgent Genetics with a rating of Outperform and set a new price target of $45.00
Core Revenue of $73.5 million grows 16% year-over-year Reiterating Full Year 2025 Core Revenue Guidance of $310 million Non-GAAP income of $1.2 million, or $0.04 per share; GAAP loss of $11.5 million, or ($0.37) per share Ended Q1 with $814.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.60 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025. First Quarter 2025 Results: Total Revenue of $
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2025 financial results before the market opens on Friday, May 2, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is a te
NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P